Skip to content

Rafael Holdings, Inc. RFL Other accrued liabilities

Other accrued liabilities at other companies

Polaryx Therapeutics, Inc.
 logo
Polaryx Therapeutics, Inc. PLYX

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+178%
P/S174×+90.2×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s other accrued liabilities?
Rafael Holdings, Inc. (RFL) reported other accrued liabilities of $156K in Q1 2026.
How has Rafael Holdings, Inc.'s other accrued liabilities changed year-over-year?
Rafael Holdings, Inc.'s other accrued liabilities decreased by 64.0% year-over-year, from $433K to $156K.
What is the long-term trend for Rafael Holdings, Inc.'s other accrued liabilities?
Over 2 years (2023 to 2025), Rafael Holdings, Inc.'s other accrued liabilities has grown at a 12.8% compound annual growth rate (CAGR), from $77K to $98K.